Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

What this study is about

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

Who can join (things the study team will check)

✅ You may be able to join if…

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at screening and immediately prior to start of administration of study treatment.
• Individuals with ECOG Performance Status of 2 solely due to local symptoms of myeloma (e.g., pain) are eligible
• MM diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria
• Received one to three lines of prior therapy that included at least two consecutive cycles of either of the following: A regimen containing an anti-CD38 therapy, a regimen containing lenalidomide
• Participants must have measurable disease during screening

🚫 You may not be able to join if…

• Known history of amyloidosis (e.g., positive Congo Red stain or equivalent in tissue biopsy or documented within serum amyloid P component scan)
• Plasma cell leukemia or circulating plasma cell count exceeding 500 cells/liter (L) or 5% of the peripheral blood white cells
• GI disease that might significantly alter absorption of oral drugs
• Participants must not have any ongoing CNS disease or non-secretory myeloma

Where this trial is running

• City of Hope National Medical Center, Duarte, California, United States
• City of Hope - Lennar Foundation Cancer Center, Irvine, California, United States
• MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C., District of Columbia, United States
• Emory University Hospital Midtown, Atlanta, Georgia, United States
• Novant Health Cancer Institute, Charlotte, North Carolina, United States
• Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States
• TriHealth Cancer and Blood Institute, Cincinnati, Ohio, United States
• Hamilton Health Sciences - Juravinski Cancer Centre, Hamilton, Ontario, Canada
• HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
• Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
• UKSH, Campus Kiel, Kiel, Germany
• Evangelismos General Hospital of Athens, Athens, Greece

+ 28 more sites.

Who to contact

Reference Study ID Number: CO46096 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 · global-roche-genentech-trials@gene.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07555938.